Zhifei Biological secures patents for dysentery and COVID vaccines

Chongqing Zhifei Biological Products has been granted two invention patents by China's National Intellectual Property Administration.

The first patent covers a preparation method for a bivalent dysentery conjugate combined vaccine, applied for in June 2022. The second patent relates to a novel COVID-19 influenza combined vaccine and its preparation method, with the application filed in February 2024.

Both patents were granted on August 22, 2025, during the company's research and development of its Shigella bivalent conjugate vaccine and combined vaccines.